echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > New research from the University of Washington reveals that manipulating the gut flora can reduce neurodegeneration in Alzheimer's disease!

    New research from the University of Washington reveals that manipulating the gut flora can reduce neurodegeneration in Alzheimer's disease!

    • Last Update: 2023-02-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    This article is the original of Translational Medicine Network, please indicate the source for reprinting

    Author: Mia

    There is growing evidence that the trillions of microbes that normally live in our guts, the so-called gut flora, have a profound impact
    on how our bodies function.
    Members of this microflora are able to produce vitamins, help us digest food, prevent the overgrowth of harmful bacteria, regulate the immune system, etc
    .
    A new study from Washington University School of Medicine in St.
    Louis has found that the gut microbiota also plays a key role
    in our brain health.

    Today, researchers at Washington University School of Medicine in St.
    Louis published a study
    in Science titled "ApoE isoform– and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy.
    " 。 The study, conducted in mice, found that gut bacteria — in part by producing compounds such as short-chain fatty acids — influence the behavior of immune cells throughout the body, including cells
    in the brain that can damage brain tissue and exacerbate neurodegeneration in conditions such as Alzheimer's disease.

    DOI: 10.
    1126/science.
    add1236

    Research background

     01 

    Alzheimer's disease (AD) is characterized by early deposition of amyloid β (Aβ) plaques, followed by pathological tau accumulation
    .
    Although Aβ is a necessary factor for the onset of AD, its own accumulation is not sufficient for neurodegeneration and cognitive decline
    .
    In contrast, pathological tau accumulation is strongly associated
    with neurodegeneration and cognitive decline in AD and primary tau disease.
    There is growing evidence that the gut flora of people with Alzheimer's disease is different from
    that of healthy people.
    But it's unclear whether these differences are a cause or a consequence of the disease, or both, and what effect altering the microbiota might have on the course of the disease
    .

    To date, animal studies have focused on how alterations in the gut microbiota affect Aβ pathology, rather than tau disease and neurodegeneration
    .
    In addition, recent studies have shown that apolipoprotein E (ApoE) subtypes strongly influence AD risk and modulate tau-mediated neurodegeneration, with different effects
    on the gut microbiota.
    Therefore, it is necessary to further study the effect of
    intestinal flora on tau protein pathology and neurodegeneration.

    Intestinal flora influences tau-mediated neurodegeneration

     02 

    The researchers altered the gut microbiome
    of mice susceptible to Alzheimer's-like brain injury and cognitive impairment.
    The mice were genetically modified to express a mutated form of the human brain protein tau, which accumulates at 9 months of age and causes neuronal damage and brain atrophy
    .
    They also carry a variant of the human apolipoprotein E gene (APOE), a major genetic risk factor
    for Alzheimer's disease.
    People who carry one copy of the APOE4 gene variant are 3 to 4 times
    more likely to develop the disease than those who carry the more common APOE3 variant.

    The researchers separately evaluated these mice in rearing under sterile (GF) conditions and early in life with short-term antibiotic (ABX) treatment
    .
    When the genetically modified mice were raised under sterile conditions from birth, they did not acquire gut microbiota, and then by 40 weeks of age, their brains were much less damaged than mice with normal flora
    .

    When these mice were housed under normal, non-sterile conditions, they developed a normal flora
    .
    However, after taking a course of antibiotics at two weeks of age, the bacterial composition of their flora was permanently altered
    .
    For male mice, brain damage was reduced at 40 weeks of age, but there was no significant change
    in neurodegeneration in female mice.
    In addition, the protective effect of altered microbiota was more pronounced
    in male mice carrying the APOE3 variant than in male mice carrying the high-risk APOE4 variant.

    Further morphological and transcriptome analysis of astrocytes and microglia revealed manipulation of the gut flora to push glial cells into a more homeosta-like state, suggesting that gut microbiota strongly influences neuroinflammation and tau-mediated neurodegeneration
    .
    Microbiome and metabolite analysis showed that short-chain fatty acids (SCFAs) produced by microbes are mediators
    of neuroinflammation-neurodegenerative axis.
    The researchers supplemented mice with the APOE4 variant with SCFAs, which resulted in more reactive glial morphology and gene expression and an increase
    in p-tau pathology.

    Research significance

     03 

    This study may provide important insights into how the microbiota affects tau-mediated neurodegeneration and suggest therapies that alter gut microbes may influence the onset or progression
    of neurodegenerative diseases.

    Dr.
    David M.
    Holtzman, the study's senior author, suggests that for mice genetically destined to develop neurodegenerative diseases, manipulating the microbiome before the animals begin to show signs of damage may have the potential to slow or prevent neurodegenerative diseases
    .
    This is equivalent to a person in late middle age who starts treatment
    while his cognitive abilities are still normal but on the verge of impairment.
    If treatment can be started on adult animal models of such genetic sensitization before neurodegeneration begins to become apparent and proven effective, it can be further tested
    in humans.

    Resources:

    style="margin: 0px 0px 15px;white-space: normal;padding: 0px;box-sizing: border-box;"> style="white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;">Note: This article is intended to introduce the progress of medical research and cannot be used as a reference
    for treatment options.
    If you need health guidance, please go to a regular hospital
    .

    Referrals, live broadcasts/events

    01/12 14:00-16:00 Online

    Olink Multiomics Cohort Forum

    Scan the code to participate for free

    03/02-03 09:00-18:00 Shanghai

    The 2nd Yangtze River Delta Single-cell Omics Technology Application Forum

    Scan the code to participate for free

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.